All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2004-001103-35 | Exemestane in Advanced or Recurrent Endometrial Carcinoma. A multicentre non-randomized Phase II study | not-yet-due | |
Exempt | 2004-001356-37 | Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer | not-yet-due | |
Ongoing | 2004-002429-37 | A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2. | not-yet-due | |
Ongoing | 2004-005218-35 | A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma | not-yet-due | |
Listed as ongoing, but also has a completion date and reported results | 2014-004269-26 | Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal ca... | 2022-02-01 | bad-data |
Reported results | 2016-000193-38 | ENGOT-EN1/FANDANGO: A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer. | 2022-03-01 | due-trials |
Not reported | 2016-001848-20 | A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive ad... | 2022-04-29 | due-trials |
Reported results | 2017-002805-36 | NSGO-OV-UMB1; ENGOT OV30: A phase II umbrella trial in patients with relapsed ovarian cancer. Vaiheen II usean hoitohaaran tutkimus uusiutunutta munasarjasyöpää sairastavilla potilailla. | 2021-12-31 | due-trials |
Reported results Terminated | 2018-003756-20 | A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer | 2019-10-10 | due-trials |
Other | 2020-004738-39 | A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer. Τυχαιοποιημένη κλινική δοκιμή για τη διε... | not-yet-due | |
Reported results Terminated | 2020-005990-29 | An Early Phase Randomised Trial of APX005M and radiation therapy in combination with chemotherapy in BRCAwt Patients with Recurrent Ovarian Cancer. ENGOT-OV64/NSGO-CTU-SOLERO | 2023-10-28 | due-trials |